Figure 3

Passive transfer of maternal antibodies provides protection in 4-week-old ARPV/ZIKV-immunized mice. Six-week-old C57BL/6J mice (n = 3) were inoculated subcutaneously (s.c.) with the indicated agents or with saline (PBS), and mated with naïve males. Four-week-old pups (n = 6–10) were challenged with a lethal dose of 1 × 10⁵ plaque forming units (PFU) of ZIKV DakAr D 41524 or PBS administered s.c. at 30 days post immunization as shown in study schematic (a). Weight change (b) and survival (c) was measured 1–14 days post challenge. Plaque Reduction Neutralizing Tests (PRNT₅₀) were done using sera collected from dams 4 weeks post immunization, and pups 3 weeks and 4 weeks post birth (d). Viremia was measured from sera collected on days 1–4 days post challenge (e). Limit of detection is indicated by the dotted line. Data points represent mean values and error bars represent the standard deviation. Significance was determined by two-way ANOVA, mixed effect analyses, or log-rank (Mantel–Cox) test when necessary. Unless otherwise marked, asterisks indicate significance compared to healthy controls (PBS): p ≤ 0.033 (*), and p ≤ 0.0001 (****). Unless otherwise marked, there was no significant difference between PBS and ARPV/ZIKV groups.